Literature DB >> 10446079

Angiotensin-converting enzyme gene polymorphism and carotid wall thickening in a community population.

J Hung1, B M McQuillan, M Nidorf, P L Thompson, J P Beilby.   

Abstract

The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene has been associated with an increased risk of coronary heart disease, but whether it is a risk factor for underlying atherosclerosis remains unclear. Therefore, we examined to see whether the ACE gene deletion polymorphism was associated with carotid wall thickening and atherosclerotic plaque formation in a large randomly selected community population. A total of 1111 subjects, aged 27 to 77 years, with an equal male:female ratio and equal numbers in each age decile, were randomly selected from the Perth community population. Mean common carotid intima-medial wall thickness (IMT) and focal plaque formation were assessed by high-resolution B-mode ultrasound. The ACE gene I/D polymorphism was detected by PCR. The distribution of the ACE genotypes conformed to the Hardy-Weinberg equilibrium (DD, 31.0%; ID, 48.4%; and II, 20.6%). The D allele was strongly correlated in a codominant fashion with plasma ACE activity (r(s)=0.53, P<0.0001), and accounted for 33% of the total variance in circulating ACE activity. No significant differences among the ACE genotypes were found with respect to age, sex, and conventional risk variables, including a history of hypertension and vascular disease. The average mean IMT and prevalence of increased IMT and focal plaque were not significantly different among genotypes in the overall population or in the subset (n=852) who were conventionally low risk by Framingham coronary heart disease risk score. Logistic regression analysis selected age, systolic blood pressure, pack-years of smoking, LDL cholesterol level, waist/hip ratio, and history of hypertension, but not the D allele, as multivariate predictors of increased IMT and carotid plaque formation. We conclude that, although the ACE I/D polymorphism is strongly related to ACE activity, it is not a risk predictor of carotid wall thickening or focal plaque formation when examined in a large randomly selected community population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446079     DOI: 10.1161/01.atv.19.8.1969

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

1.  A study of gene--environment interaction on the gene for angiotensin converting enzyme: a combined functional and population based approach.

Authors:  F A Sayed-Tabatabaei; A F C Schut; A Hofman; A M Bertoli-Avella; J Vergeer; J C M Witteman; C M van Duijn
Journal:  J Med Genet       Date:  2004-02       Impact factor: 6.318

Review 2.  Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism.

Authors:  Cinzia Fatini; Serena Guiducci; Rosanna Abbate; Marco Matucci-Cerinic
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

3.  15-Lipoxygenase gene variants are associated with carotid plaque but not carotid intima-media thickness.

Authors:  Pamela A McCaskie; John P Beilby; Joseph Hung; Caroline M L Chapman; Brendan M McQuillan; Brenda L Powell; Peter L Thompson; Lyle J Palmer
Journal:  Hum Genet       Date:  2008-04-05       Impact factor: 4.132

4.  RAS gene polymorphisms, classical risk factors and the advent of coronary artery disease in the Portuguese population.

Authors:  Ana I Freitas; Isabel Mendonça; Maria Brión; Miguel M Sequeira; Roberto P Reis; Angel Carracedo; António Brehm
Journal:  BMC Cardiovasc Disord       Date:  2008-07-17       Impact factor: 2.298

5.  Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer's type in an elderly Arab population in Wadi Ara, Israel.

Authors:  Abdalla Bowirrat; Jing Cui; Kristin Waraska; Robert P Friedland; Marlene Oscar-Berman; Lindsay A Farrer; Amos Korczyn; Clinton T Baldwin
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.